{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:26:34Z","timestamp":1785795994453,"version":"3.56.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1245\/s10434-022-12694-8","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T19:08:04Z","timestamp":1666984084000},"page":"861-870","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Docetaxel, Cisplatin, and 5-FU Triplet Therapy as Conversion Therapy for Locoregionally Advanced Unresectable Esophageal Squamous Cell Carcinoma"],"prefix":"10.1245","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9793-9273","authenticated-orcid":false,"given":"Wing-Lok","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheuk-Wai","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian Yu-Hong","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence Hon-Ting","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian Tin-Chung","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Pui-Ying","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. K.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty Tze-Ting","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emina Edith","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siu-Yin","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka-On","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"issue":"3","key":"12694_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin."},{"issue":"1","key":"12694_CR2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/annonc\/mdy498","volume":"30","author":"K Muro","year":"2019","unstructured":"Muro K, Lordick F, Tsushima T, et al. Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol. 2019;30(1):34\u201343. https:\/\/doi.org\/10.1093\/annonc\/mdy498.","journal-title":"Ann Oncol."},{"issue":"suppl 5","key":"12694_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/annonc\/mdw329","volume":"27","author":"F Lordick","year":"2016","unstructured":"Lordick F, Mariette C, Haustermans K, Obermannov\u00e1 R, Arnold D, ESMO Guidelines Committee. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):50\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdw329.","journal-title":"Ann Oncol."},{"issue":"23","key":"12694_CR4","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1200\/JCO.20.00866","volume":"38","author":"MA Shah","year":"2020","unstructured":"Shah MA, Kennedy EB, Catenacci DV, et al. Treatment of locally advanced esophageal carcinoma: ASCO Guideline. J Clin Oncol. 2020;38(23):2677\u201394. https:\/\/doi.org\/10.1200\/JCO.20.00866.","journal-title":"J Clin Oncol."},{"key":"12694_CR5","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Esophageal and Esophaogastric Junction Cancers. Version: 2.2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/esophageal.pdf"},{"issue":"22","key":"12694_CR6","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P van Hagen","year":"2012","unstructured":"van Hagen P, Hulshof MC, van Lanschot JJ, CROSS Group, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074\u201384. https:\/\/doi.org\/10.1056\/NEJMoa1112088.","journal-title":"N Engl J Med"},{"issue":"18","key":"12694_CR7","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1200\/JCO.20.03614","volume":"39","author":"BM Eyck","year":"2021","unstructured":"Eyck BM, van Lanschot JJB, Hulshof MCCM, CROSS Study Group, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial. J Clin Oncol. 2021;39(18):1995\u20132004. https:\/\/doi.org\/10.1200\/JCO.20.03614.","journal-title":"J Clin Oncol."},{"issue":"24","key":"12694_CR8","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1056\/NEJM199206113262403","volume":"326","author":"A Herskovic","year":"1992","unstructured":"Herskovic A, Martz K, Al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326(24):1593\u20138. https:\/\/doi.org\/10.1056\/NEJM199206113262403.","journal-title":"N Engl J Med."},{"issue":"5","key":"12694_CR9","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1200\/JCO.2002.20.5.1167","volume":"20","author":"BD Minsky","year":"2002","unstructured":"Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94\u201305) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20(5):1167\u201374. https:\/\/doi.org\/10.1200\/JCO.2002.20.5.1167.","journal-title":"J Clin Oncol."},{"issue":"3","key":"12694_CR10","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S1470-2045(14)70028-2","volume":"15","author":"T Conroy","year":"2014","unstructured":"Conroy T, Galais MP, Raoul JL, F\u00e9d\u00e9ration Francophone de Canc\u00e9rologie Digestive and UNICANCER-GI Group, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5\/ACCORD17): final results of a randomised, phase 2\/3 trial. Lancet Oncol. 2014;15(3):305\u201314. https:\/\/doi.org\/10.1016\/S1470-2045(14)70028-2.","journal-title":"Lancet Oncol."},{"issue":"20","key":"12694_CR11","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1200\/JCO.18.02122","volume":"37","author":"Y Chen","year":"2019","unstructured":"Chen Y, Ye J, Zhu Z, et al. Comparing paclitaxel plus fluorouracil versus cisplatin plus fluorouracil in chemoradiotherapy for locally advanced esophageal squamous cell cancer: a randomized, multicenter, phase III clinical trial. J Clin Oncol. 2019;37(20):1695\u2013703. https:\/\/doi.org\/10.1200\/JCO.18.02122.","journal-title":"J Clin Oncol."},{"issue":"31","key":"12694_CR12","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","volume":"24","author":"E Van Cutsem","year":"2006","unstructured":"Van Cutsem E, Moiseyenko VM, Tjulandin S, V325 Study Group, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991\u20137. https:\/\/doi.org\/10.1200\/JCO.2006.06.8429.","journal-title":"J Clin Oncol."},{"issue":"3","key":"12694_CR13","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1200\/JCO.2006.06.8429","volume":"75","author":"E Van Miyazaki","year":"2015","unstructured":"Miyazaki T, Sohda M, Tanaka N, et al. Phase I\/II study of docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy in patients with advanced esophageal cancer. Cancer Chemother Pharmacol. 2015;75(3):449\u201355. https:\/\/doi.org\/10.1007\/s00280-014-2659-6. Epub 2014 Dec 28.","journal-title":"Cancer Chemother Pharmacol."},{"issue":"2","key":"12694_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/dote.12485","volume":"30","author":"Y Miyawaki","year":"2017","unstructured":"Miyawaki Y, Nakajima Y, Kawada K, Okada T, Tokairin Y, Kawano T. Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma. Dis Esophagus. 2017;30(2):1\u20138. https:\/\/doi.org\/10.1111\/dote.12485.","journal-title":"Dis Esophagus."},{"key":"12694_CR15","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, de Vries E, et al. RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132\u20137. https:\/\/doi.org\/10.1016\/j.ejca.2016.03.081.","journal-title":"Eur J Cancer."},{"key":"12694_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11\u201320.","journal-title":"N Engl J Med."},{"issue":"10184","key":"12694_CR17","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, FLOT4-AIO Investigators, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393(10184):1948\u201357.","journal-title":"Lancet."},{"issue":"4_suppl","key":"12694_CR18","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1200\/JCO.2022.40.4_suppl.238","volume":"40","author":"K Kato","year":"2022","unstructured":"Kato K, Ito Y, Daiko H, et al. A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study. J Clin Oncol. 2022;40(4_suppl):238. https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.238.","journal-title":"J Clin Oncol."},{"key":"12694_CR19","doi-asserted-by":"crossref","unstructured":"Matsuda S, Kitagawa Y, Takemura R, Okui J, Okamura A, Kawakubo H, Muto M, Kakeji Y, Takeuchi H, Watanabe M, Doki Y. Real-world evaluation of the efficacy of neoadjuvant DCF over CF in esophageal squamous cell carcinoma: propensity score matched analysis from 85 Authorized Institutes for Esophageal Cancer in Japan. Ann Surg. 2022.","DOI":"10.1097\/SLA.0000000000005533"},{"issue":"10","key":"12694_CR20","first-page":"3535","volume":"31","author":"T Yokota","year":"2011","unstructured":"Yokota T, Hatooka S, Ura T, et al. Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. Anticancer Res. 2011;31(10):3535\u201341.","journal-title":"Anticancer Res."},{"issue":"2","key":"12694_CR21","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1245\/s10434-020-08865-0","volume":"28","author":"T Abe","year":"2021","unstructured":"Abe T, Higaki E, Hosoi T, et al. Long-term outcome of patients with locally advanced clinically unresectable esophageal cancer undergoing conversion surgery after induction chemotherapy with docetaxel plus cisplatin and 5-fluorouracil. Ann Surg Oncol. 2021;28(2):712\u201321. https:\/\/doi.org\/10.1245\/s10434-020-08865-0.","journal-title":"Ann Surg Oncol."},{"issue":"8","key":"12694_CR22","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1007\/s00268-019-05000-3","volume":"43","author":"M Takeuchi","year":"2019","unstructured":"Takeuchi M, Kawakubo H, Mayanagi S, et al. The benefits of docetaxel plus cisplatin and 5-fluorouracil induction therapy in conversion to curative treatment for locally advanced esophageal squamous cell carcinoma. World J Surg. 2019;43(8):2006\u201315. https:\/\/doi.org\/10.1007\/s00268-019-05000-3.","journal-title":"World J Surg."},{"issue":"13","key":"12694_CR23","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","volume":"384","author":"RJ Kelly","year":"2021","unstructured":"Kelly RJ, Ajani JA, Kuzdzal J, CheckMate 577 Investigators, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384(13):1191\u2013203. https:\/\/doi.org\/10.1056\/NEJMoa2032125.","journal-title":"N Engl J Med."},{"issue":"5","key":"12694_CR24","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K, CheckMate 648 Trial Investigators, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386(5):449\u201362. https:\/\/doi.org\/10.1056\/NEJMoa2111380.","journal-title":"N Engl J Med."},{"issue":"10302","key":"12694_CR25","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun JM, Shen L, Shah MA, KEYNOTE-590 Investigators, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(21)01234-4.","journal-title":"Lancet."},{"issue":"10","key":"12694_CR26","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1001\/jama.2021.12836","volume":"326","author":"H Luo","year":"2021","unstructured":"Luo H, Lu J, Bai Y, ESCORT-1st Investigators, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA. 2021;326(10):916\u201325. https:\/\/doi.org\/10.1001\/jama.2021.12836.","journal-title":"JAMA."},{"key":"12694_CR27","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/jso.21510","volume":"101","author":"RH Kim","year":"2010","unstructured":"Kim RH, Takabe K. Methods of esophagectomy for cancer: a systematic review. J Surg Oncol. 2010;101:527\u201333.","journal-title":"J Surg Oncol."},{"key":"12694_CR28","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/00000658-200103000-00006","volume":"233","author":"BP Whooley","year":"2001","unstructured":"Whooley BP, Law S, Murthy SC, et al. An analysis of reduced deaths and complication rates after esophageal. Ann Surg. 2001;233:338\u201344.","journal-title":"Ann Surg."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12694-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-022-12694-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12694-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T14:06:07Z","timestamp":1672668367000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-022-12694-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["12694"],"URL":"https:\/\/doi.org\/10.1245\/s10434-022-12694-8","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,28]]},"assertion":[{"value":"15 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ka On Lam Grants\/Research Support: Bayer, Roche, Taiho. Advisory Board\/Honoraria: Amgen, Bayer, BMS, Daiich-Sankyo, Eli Lilly, Lintonpharm, Merck, MSD, Novartis, Roche, Sanofi-Aventis, Taiho.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}